Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2553291 | Life Sciences | 2006 | 5 Pages |
Abstract
The findings indicate that selective sst1, sst2 and sst5 receptors agonists, SST/DA chimera and D2-dopamine receptor agonist bromocriptine affect the viability of some, but not all, “clinically non-functioning” pituitary adenomas in vitro. The most effective was bromocriptine. The investigated somatostatin analogs including SST/DA chimera exerted roughly similar inhibitory effects. Further studies are needed to fully evaluate the potential usefulness of these compounds in the pharmacological treatment of “non-functioning” pituitary tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
A. Gruszka, J. Kunert-Radek, A. Radek, H. Pisarek, J. Taylor, J.Z. Dong, M.D. Culler, M. Pawlikowski,